New drug trial aims to help kidney patients lose weight and improve health
NCT ID NCT07176663
Summary
This study will test the safety and effects of the medication tirzepatide (brand name Spartina) in people with chronic kidney failure who also have obesity or diabetes. It aims to see if the drug can help with weight loss and improve measures of kidney function and blood sugar control. The trial will involve 15 participants and will track their health over three months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Nooshin Dalili
Tehran, 1666663421, Iran
Conditions
Explore the condition pages connected to this study.